S3 EXABS-100-AML What is New in the WHO Classification of AML Sanam Loghavi, MD1,* 1MD Anderson Cancer Center, Department of Hematopathology, 1515 Holcombe Blvd, Houston, TX, 77027, USA *Corresponding author: sloghavi@mdanderson.org Keywords Classification, AML, WHO, ICC, molecular Introduction The 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours1 provides a hierarchically-driven catalogue of hematologic neoplasms. The updated classification introduces a series of changes to the classification of acute myeloid leukemias (AML), with emphasis on molecular genetic findings, expanding the category of “acute myeloid leukemias with defining genetic abnormalities”. This presentation will provide a comprehensive overview of the WHO 5th updates in the classification of AML. Results and Conclusions The updated classification of AML places added emphasis on molecular genetic abnormalities. The category of “acute myeloid leukemias with defining genetic abnormalities” has been expanded and includes those previously recognized in the WHO 2016 including acute promyelocytic leukemia with PML::RARA and the core binding factor AMLs, as well as the introduction of several novel or modified subtypes where the 20% blast requirement for establishing a diagnosis of AML has been eliminated. These include AML with KMT2A rearrangement, MECOM rearrangement, NUP98 rearrangement, and AML with NPM1 mutation. AML with BCR::ABL1 fusion and AML with CEBPA mutation are also recognized in the category of AML with defining genetic Figure 1 WHO 5th ed Classification of Acute Myeloid Leukemia. Adapted from ref1
RkJQdWJsaXNoZXIy MTk3NTQxMg==